SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51078Mediation of the Acute Stress Response by the Skeleton cell.comnigel bates-9/12/2019
51077aarp.org Would suggest you visit the AARP website and note the different topicsArthur Radley-9/11/2019
51076Thanks to the three of you. I have a tendency to go down a rabbit-hole of optimiA.J. Mullen-9/11/2019
51075doctors like medicare because it pays them better than private plans that peoplesoftware salesperson-9/11/2019
51074are Medigap Coverage and Supplemental Coverage synonymous?) - - yes want to be software salesperson-9/11/2019
51073[OT]—You ask some good questions that will require deliberation for anyone to anDewDiligence_on_SI-9/11/2019
51072I have been on Medicare for a couple of years. What I did was to work the procesThehammer-9/11/2019
51071OT A question for my elders. I'm getting close to 65 so must chose my MedicA.J. Mullen-9/11/2019
51070I defer to your views on dosage, as that is somewhat beyond my area of expertiseArt Bechhoefer-9/10/2019
51069Dose response and minimal effective dose....(what I believe is early P1 data) viMiljenko Zuanic-9/10/2019
51068Ideally, reducing dosage while maintaining efficacy is to the advantage of the dArt Bechhoefer-9/10/2019
51067Ocaliva P3 results were weak, and (as Dew mentioned) even IF approved for NASH sMiljenko Zuanic-9/9/2019
51066 Should we also be looking at ICPT, which, like the others has declined in priDewDiligence_on_SI19/9/2019
51065Thanks for your additional views on VKTX and MDGL. Should we also be looking atArt Bechhoefer-9/9/2019
51064It is not single presentation,... it is talk about candidate in general. First pMiljenko Zuanic19/9/2019
51063FLD is one of the NASH precursor conditions, and it is hard to me believing thatMiljenko Zuanic-9/9/2019
51062Regarding VKTX, if I misinterpreted the information provided in the most recent Art Bechhoefer-9/9/2019
51061Peter, I think it was about ten to fifteen years ago, after ACAD had been deserIan@SI-9/9/2019
51060Can you be more specific wrt statements he made and the presentation (link) if ysemi_infinite -9/9/2019
51059<Also, note that its main drug is being developed initially not for NASH but Miljenko Zuanic-9/9/2019
51058I think that in the richest nation on earth, when push comes to shove, we pay foSickEconomist-9/8/2019
51057Is anyone here paying attention to NWBO. While it's Phase 3 trial for DCVaxGary Mohilner-9/7/2019
51056A lot of pharma companies in blue states though. Funny thing is hospital/doctor hmpa-9/7/2019
51055Thanks for the kind words. Family emergencies have me in Deep South for a bit. TRobohogs-9/7/2019
51054Hi Jon, I'm sorry to hear about the Ritalin/Concerta concern with your son.da_spot-9/7/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News